Your Messages Inbox
Your Article Summary
See Latest ArticlesONGLYZA (saxagliptin) Cardiovascular Profile Acceptable According to FDA Advisory Committee
Bristol Myers-Squibb Company, 04/02/09
Bristol-Myers Squibb Company and AstraZeneca announced that the U.S. Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee determined that the data supporting the new drug application for ONGLYZA for the treatment of adults with type 2 diabetes were sufficient to rule out unacceptable cardiovascular risk relative to comparators in the program.
Today in Conferences/Meetings...keeping you current
Receive free subspecialty "5-minute updates" via email
MediGene AG presents future business plan at annual analyst conference
MediGene, 12/16/09
Summit to Tackle Rural Health I.T.
HealthDataManagement, 12/16/09
Banking Institute on HIMSS Agenda
HealthDataManagement, 12/16/09
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
Article Search
Sponsor